Atopic Dermatitis

The study will aim to understand whether systemic medications and biologics, such as dupilumab may have a positive or negative impact on COVID-19 responses in patients who have the disease.

Patients with moderate to severe atopic dermatitis who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be...

AOBiome Therapeutics, Inc. is initiating a Phase 2b clinical trial of its lead product candidate, B244, in pruritus associated with atopic dermatitis.

B244 is a first-in-class, topical formulation of...

Lebrikizumab improved symptoms and quality of life in a rapid, dose-dependent manner across a range of atopic dermatitis-specific and other measures compared with placebo.

Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual ...

Both 40 and 80 mg doses of gusacitinib resulted in 50 percent and 66 percent improvement, respectively, in the mTLSS pruritus sub-score at week 16.

Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adu...

Dupixent is the only biologic medicine approved for this population.

The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).

Dupixent comes in two doses, prescribed ...